Atai Life Sciences (NASDAQ:ATAI) Full Year 2023 Results

Key Financial Results

• Net loss: US$40.2m (loss narrowed by 74% from FY 2022).
• US$0.25 loss per share (improved from US$0.98 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Atai Life Sciences EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 53%. Earnings per share (EPS) exceeded analyst estimates by 21%.

Looking ahead, revenue is forecast to grow 66% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are up 21% from a week ago.

Risk Analysis

Be aware that Atai Life Sciences is showing 4 warning signs in our investment analysis and 2 of those are potentially serious...

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.